6-K - CLLS - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report ofForeign Private Issuer

Pursuant to Rule 13a-16 or15d-16

under the Securities Exchange Act of 1934

Date of Report: June 28, 2024

Commission File Number: 001-36891

Cellectis S.A.

(ExactName of registrant as specified in its charter)

8, rue de laCroix Jarry

75013 Paris, France

+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Cellectis S.A.

Cellectis S.A. (the “Company”) held its Combined General Meeting of Shareholders (the “Meeting”) on June 28, 2024.

The voting results of the Meeting, which is attached as Exhibit 99.1 hereto, is incorporated by reference herein.

EXHIBITS

Exhibit	Title
99.1	Voting Results for the Combined General Meeting of Shareholders

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CELLECTIS S.A.
June 28, 2024	By:	/s/ André Choulika
		André Choulika
		Chief Executive Officer

EX-99.1

Exhibit 99.1

CELLECTIS ANNUAL SHAREHOLDERS MEETING – June 28. 2024

VOTE RESULTS

Ordinary Resolutions

NB
		Votes		%		Votes		%		Votes		%
1	approval of the annual financial statements for the financial year ended December 31,2023
	1	carried	45 182 051		99.60	%	179 689		0.40	%	17 048		—	45 361 740	40 493 776	40.455	%	0	0	40.455	%
2	approval of the consolidated financial statements for the financial year ended December 31, 2023
	2	carried	45 164 516		99.60	%	180 689		0.40	%	33 583		—	45 345 205	40 493 776	40.455	%	0	0	40.455	%
3	allocation of the results for the financial year ended December 31,2023
	3	carried	45 178 716		99.60	%	180 489		0.40	%	19 583		—	45 359 205	40 493 776	40.455	%	0	0	40.455	%
4	allocation of losses carried forward to the “share premium” account
	4	carried	45 070 113		99.36	%	288 592		0.64	%	20 083		—	45 358 705	40 493 776	40.455	%	0	0	40.455	%
5	review of the agreements considered in articles L. 225-38 et seq. of the French Commercial Code (financing agreement with Bpifrance)
	5	carried	36 404 916		99.45	%	201 042		0.55	%	20 083		—	36 605 958	34 620 529	34.588	%	8 752 747	0	40.455	%

1/5

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2024

VOTE RESULTS

NB
		Votes		%		Votes		%		Votes		%
6	review of the agreements considered in articles L. 225-38 et seq. of the French Commercial Code (subsidy and repayable advance agreement with Bpifrance)
	6	carried	36 402 945		99.45	%	203 013		0.55	%	20 083		—	36 605 958	34 620 529	34.588	%	8 752 747	0	40.455	%
7	renewal of the appointment of Mr. André Choulika as a member of the board of directors
	7	carried	44 631 510		98.39	%	729 346		1.61	%	17 932		—	45 360 856	40 493 776	40.455	%	0	0	40.455	%
8	renewal of the appointment of Mr. David Sourdive as a member of the board of directors
	8	carried	43 090 151		94.99	%	2 270 705		5.01	%	17 932		—	45 360 856	40 493 776	40.455	%	0	0	40.455	%
9	renewal of the appointment of J.M.H. Conseil as statutory auditor
	9	carried	33 583 149		76.76	%	10 169 651		23.24	%	1 625 988		—	43 752 800	40 493 776	40.455	%	0	0	40.455	%
10	appointment of KPMG as statutory auditor
	10	carried	45 156 134		99.55	%	204 746		0.45	%	17 908		—	45 360 880	40 493 776	40.455	%	0	0	40.455	%
11	authorization to the Board of Directors to buy back shares of the Company
	11	carried	44 846 482		98.87	%	514 375		1.13	%	17 931		—	45 360 857	40 493 776	40.455	%	0	0	40.455	%
12	authorization to be granted to the Board of Directors to reduce the share capital by cancelling shares under the authorization for to buy back its own shares
	12	carried	45 052 759		99.33	%	305 495		0.67	%	20 534		—	45 358 254	40 493 776	40.455	%	0	0	40.455	%

2/5

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2024

VOTE RESULTS

Extraordinary Resolutions

N°
		Votes		%		Votes		%		Votes		%
13	up-date of Article 24 of the articles of association “Loss of one half of share capital” in order to comply with legal provisions
	13	carried	45 151 875		99.55	%	206 370		0.45	%	20 543		—	45 358 245	40 493 776	40.455	%	0	0	40.455	%
14	delegation of authority to be granted to the Board of Directors to increase the share capital immediately or in the future by issuing ordinary shares<br>and/or any securities. with cancellation of<br>shareholders’ preferential subscription rights in favor of the European Investment Bank or of other entities<br>that may succeed EIB. according to any finance agreement entered or be entered
	14	carried	43 926 971		96.87	%	1 418 183		3.13	%	33 634		—	45 345 154	40 493 776	40.455	%	0	0	40.455	%
15	delegation of authority to be granted to the Board of Directors to increase the share capital immediately or in the future by issuing ordinary shares<br>and/or any securities, with cancellation of<br>shareholders’ preferential subscription rights in favor of a category of persons meeting specified<br>characteristics (investors with experience in the health or biotech sector)
	15	carried	44 978 073		99.16	%	381 081		0.84	%	19 634		—	45 359 154	40 493 776	40.455	%	0	0	40.455	%
16	delegation of authority to be granted to the Board of Directors to increase the share capital immediately or in the future by issuing ordinary shares or<br>any securities. with cancellation of<br>shareholders’ preferential subscription rights in favor of a category of persons meeting specified characteristics<br>(credit institutions. investment services providers or members of an investment pool guaranteeing the completion of the<br>considered issue)
	16	carried	44 971 324		99.14	%	388 551		0.86	%	18 913		—	45 359 875	40 493 776	40.455	%	0	0	40.455	%
17	delegation of authority to be granted to the Board of Directors to increase the share capital immediately or in the future by issuing ordinary shares or<br>any other securities, with cancellation of<br>shareholders’ preferential subscription rights in favor of a category of persons meeting specified<br>characteristics (industrial companies. institutions or entities active in the health or biotechnology sector)
	17	carried	44 957 300		99.14	%	388 511		0.86	%	32 977		—	45 345 811	40 493 776	40.455	%	0	0	40.455	%

3/5

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2024

VOTE RESULTS

N°
		Votes		%		Votes		%		Votes		%
18	delegation of authority to be granted to the Board of Directors to increase the capital by issuing ordinary shares or any other securities with<br>cancellation of shareholders’ preferential subscription<br>rights in favor of a category of persons meeting specified characteristics the framework of an<br>equity or bond financing agreement
	18	carried	44 971 364		99.14	%	388 511		0.86	%	18 913		—	45 359 875	40 493 776	40.455	%	0	0	40.455	%
19	delegation of authority to be granted to the Board of Directors to decide on the issuance of ordinary shares to be issued immediately or in the future<br>by the Company. with cancellation of the<br>shareholders’ preferential subscription rights, to the benefit of a category of persons meeting specified<br>characteristics within the framework of an equity financing program on the American market known as “At-the-market” or “ATM”
	19	carried	44 957 603		99.14	%	388 511		0.86	%	32 674		—	45 346 114	40 493 776	40.455	%	0	0	40.455	%
20	delegation of authority to be granted to the Board of Directors to immediately or in the future increase the share capital by issuing ordinary shares or<br>any other securities giving access to the share<br>capital. with the shareholders’ preferential subscription rights maintained
	20	carried	45 029 850		99.28	%	328 304		0.72	%	20 634		—	45 358 154	40 493 776	40.455	%	0	0	40.455	%
21	delegation of authority to be granted to the Board of Directors to increase the capital immediately or in the future through the issue of ordinary<br>shares or any securities, with cancellation of the<br>shareholders’ pre-emptive subscription rights by way of a public offering (other than the offers<br>referred to in paragraph 1° of Article L. 411-2 of the<br>French Monetary and Financial Code)
	21	carried	44 971 727		99.15	%	387 411		0.85	%	19 650		—	45 359 138	40 493 776	40.455	%	0	0	40.455	%
22	delegation of authority to be granted to the Board of Directors to increase the capital immediately or in the future through the issue of ordinary<br>shares or any securities, with cancellation of’ pre-emptive subscription rights by way of an offering referred to in paragraph 1° of Article L. 411-2 of<br>the French Monetary and Financial Code
	22	carried	44 957 703		99.11	%	401 451		0.89	%	19 634		—	45 359 154	40 493 776	40.455	%	0	0	40.455	%
23	delegation of authority to be granted to the Board of Directors to increase the amount of each of the issues with or without pre-emptive subscription<br>rights which<br>will be decided pursuant to the above delegations
	23	carried	44 981 679		99.17	%	377 478		0.83	%	19 631		—	45 359 157	40 493 776	40.455	%	0	0	40.455	%

4/5

CELLECTIS – ANNUAL SHAREHOLDERS MEETING – June 28, 2024

VOTE RESULTS

N°
		Votes		%		Votes		%		Votes		%
24	determination of the total amount of the capital increases that may be carried out under the aforementioned delegations (excluding the share capital increase<br>with upholding of the shareholders’<br>preferential subscription rights and the share capital increase in favor of the European Investment Bank or of other<br>entities that may succeed EIB. according to any finance agreement)
	24	carried	45 149 182		99.54	%	209 972		0.46	%	19 634		—	45 359 154	40 493 776	40.455	%	0	0	40.455	%
25	delegation of authority to be granted to the board of directors to increase the capital by incorporation of premiums. reserves. profits or other
	25	carried	45 115 130		99.46	%	244 026		0.54	%	19 632		—	45 359 156	40 493 776	40.455	%	0	0	40.455	%
26	authorization to be granted to the Board of Directors to grant options to subscribe for or purchase ordinary shares in the Company, entailing a waiver by the<br>shareholders of their preferential subscription<br>rights
	26	carried	35 196 342		96.19	%	1 395 967		3.81	%	8 786 479		—	36 592 309	40 493 776	40.455	%	0	0	40.455	%
27	authorization to be granted to the Board of Directors to proceed with free allocations of ordinary shares of the Company, to the benefit of employees and/or<br>corporate officers of the Company and its<br>subsidiaries, entailing the waiver by the shareholders of their preferential subscription rights
	27	carried	35 243 114		96.28	%	1 363 293		3.72	%	8 772 381		—	36 606 407	40 493 776	40.455	%	0	0	40.455	%
28	determination of the total amount of the capital increases that may be carried out by virtue of the aforementioned authorization to grant options to subscribe<br>for or purchase shares and the aforementioned<br>authorization to grant free shares
	28	carried	45 137 900		99.51	%	221 154		0.49	%	19 734		—	45 359 054	40 493 776	40.455	%	0	0	40.455	%
29	delegation of authority to be granted to the Board of Directors for the purpose of carrying out a capital increase whose subscription will be reserved for<br>members of a company savings plan established<br>pursuant to Articles L. 3332-1 et seq. of the Labor Code
	29	rejected	9 064 329		19.99	%	36 287 053		80.01	%	27 406		—	45 351 382	40 493 776	40.455	%	0	0	40.455	%

5/5